Status:
UNKNOWN
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients :
- 18 years of age and older
- with hematological malignancies and subject to allogeneic HSCT
- with health insurance coverage (bénéficiaire ou ayant droit)
- having signed a written informed consent.
- Inclusion criteria of donor
- 18 years of age and older
- with health insurance coverage (bénéficiaire ou ayant droit)
- having signed a specific written informed consent.
- Exclusion criteria of recipient and donor
- Absence of written informed consent
- Patient or donor on AME
- Patient or donor on AME or under protection by law, tutorship or curatorship
- Pregnant women
Exclusion
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04682314
Start Date
December 1 2020
End Date
July 1 2023
Last Update
December 23 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.